Lilly del Caribe Approved for Pharma Production in Puerto Rico Trade Zone
Published Date: 6/27/2025
Notice
Summary
Lilly del Caribe, Inc. in Carolina, Puerto Rico, got the green light to make pharmaceutical products in Foreign-Trade Zone 7. This means they can produce medicines with special trade benefits, helping them save money and speed up operations. The approval was finalized on June 20, 2025, so their production can move forward without delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Lilly del Caribe Authorized to Produce Pharmaceuticals
Lilly del Caribe, Inc. received authorization to produce pharmaceutical products at its facility within Subzone 7K of Foreign-Trade Zone 7 in Carolina, Puerto Rico. The FTZ Board notified the applicant on June 20, 2025 that no further review was warranted and the production activity was authorized, subject to the FTZ Act and FTZ Board regulations (including section 400.14).
FTZ Authorization Carries Trade Benefits and Faster Operations
The authorization allows Lilly del Caribe to produce medicines in Foreign-Trade Zone 7 with special trade benefits, which the notice says can help the company save money and speed up operations. The approval was finalized on June 20, 2025, enabling the company to move forward without delays.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in